Parallax Health Sciences, Inc. Watch

from S-1/A 1 page Parallax Health Sciences, Inc. Description of Oral Agreements to Extend Maturities of Certain Convertible Promissory Notes

from 10-K/A 2 pages June 4, 2019 ███████████ ███████████ ███████████ ███████████ ███████████ ███████████ ███████████ ███████████

from 10-K/A 2 pages Securities Purchase Agreement

from 10-K/A 2 pages Convertible Promissory Note

from 8-K 19 pages Event of a Partial Redemption or Conversion. as a Result, Following Any Redemption or Conversion of Any Portion of This Note, the Outstanding Principal Sum Represented by This Note May Be Less Than the Principal Sum and Accrued Interest Set Forth Below. 12% Fixed Convertible Promissory Note of Parallax Health Sciences, Inc. Issuance Date: October 23, 2019 Principal Sum: $300,000 This Note Is a Duly Authorized Fixed Convertible Promissory Note of Parallax Health Sciences, Inc., a Corporation Duly Organized and Existing Under the Laws of the State of Nevada (The “Company”), Designated as the Company's 12% Fixed Convertible Promissory Note Due April 23, 2020 (“Maturity Date”) in the Face Amount of $300,000 (The “Note”). for Value Received, the Company Hereby Promises to Pay to the Order of ███████ ██████████████ or Its Registered Assigns or Successors-In-Interest (The “Holder”) the Principal Sum of $300,000 (The “Principal Sum”) and to Pay “Guaranteed” Interest on the Principal Balance Hereof at an Amount Equivalent to 12% of the Principal Sum, to the Extent Such Principal Sum and “Guaranteed” Interest and Any Other Interest, Fees, Liquidated Damages and/or Items Due to Holder Herein Have Not Been Repaid or Converted Into the Company’s Common Stock (The “Common Stock”), in Accordance With the Terms Hereof. the Sum of $250,000 Shall Be Remitted and Delivered to the Company, and $50,000 Shall Be Retained by the Holder Through

from 8-K ~5 pages 8% Senior Secured Note

from 8-K 29 pages Registration Rights Agreement This Registration Rights Agreement (This “Agreement”) Is Made and Entered Into as of May 6, 2019, Between Parallax Health Sciences, a Nevada Corporation (The “Company”), and Each of the Several Purchasers Signatory Hereto (Each Such Purchaser, a “Purchaser” And, Collectively, the “Purchasers”). This Agreement Is Made Pursuant to the Securities Purchase Agreement, Dated as of the Date Hereof, Between the Company and Each Purchaser (The “Purchase Agreement”). the Company and Each Purchaser Hereby Agrees as Follows

from 8-K 42 pages Definitions

from 8-K 13 pages Ex 4.1 12% Convertible Promissory Note

from 8-K 21 pages Event of a Partial Redemption or Conversion. as a Result, Following Any Redemption or Conversion of Any Portion of This Note, the Outstanding Principal Sum Represented by This Note May Be Less Than the Principal Sum and Accrued Interest Set Forth Below. 12% Fixed Convertible Promissory Note of Parallax Health Sciences, Inc. Issuance Date: March 18, 2019 Total Face Value of Note: $260,000 Initial Consideration: $125,000 Initial Original Issue Discount: $5,000 Initial Principal Sum Due: $130,000 This Note Is a Duly Authorized Fixed Convertible Promissory Note of Parallax Health Sciences, Inc., a Corporation Duly Organized and Existing Under the Laws of the State of Nevada (The “Company”), Designated as the Company's 12% Fixed Convertible Promissory Note in the Principal Amount of $260,000 (The “Note”). This Note Will Become Effective Only Upon Execution by Both Parties and Delivery of the First Payment of Consideration by the Holder, Defined Below, (The “Effective Date”). for Value Received, the Company Hereby Promises to Pay to the Order of Harbor Gates Capital, LLC or Its Registered Assigns or Successors-In-Interest (The “Holder”) the Principal Sum of $260,000 (The “Principal Sum”) and to Pay “Guaranteed” Interest on the Principal Balance Hereof at an Amount Equivalent to 12% of the Principal Sum, to the Extent Such Principal Sum and “Guaranteed” Interest and Any Other Interest, Fees, Liquidated Damages and/Or

from 8-K 3 pages Convertible Debenture

from 8-K 13 pages Registration Rights Agreement Registration Rights Agreement (This "Agreement"), Dated as of November 14, 2018, by and Between Parallax Health Sciences, Inc., a Nevada Corporation (The "Company"), and Peak One Opportunity Fund, L.P., a Delaware Limited Partnership (Together With It Permitted Assigns, the “Buyer”). Capitalized Terms Used Herein and Not Otherwise Defined Herein Shall Have the Respective Meanings Set Forth in the Equity Purchase Agreement by and Between the Parties Hereto, Dated as of the Date Hereof (As Amended, Restated, Supplemented or Otherwise Modified From Time to Time, the "Purchase Agreement"). Whereas: The Company Has Agreed, Upon the Terms and Subject to the Conditions of the Purchase Agreement, to Sell to the Buyer Up to Ten Million Dollars ($10,000,000.00) of Put Shares and to Induce the Buyer to Enter Into the Purchase Agreement, the Company Has Agreed to Provide Certain Registration Rights Under the Securities Act of 1933, as Amended, and the Rules and Regulations Thereunder, or Any Similar Successor Statute (Collectively, the "Securities Act"), and Applicable State Securities Laws. Now, Therefore, in Consideration of the Promises and the Mutual Covenants Contained Herein and Other Good and Valuable Consideration, the Receipt and Sufficiency of Which Are Hereby Acknowledged, the Company and the Buyer Hereby Agree as Follows: 1. Definitions. as Used in This Agreement, the Following Terms Shall Have the Following Meanings

from 8-K 14 pages Issuance Date: November 14, 2018 Principal Amount: $125,000.00 for Value Received, Parallax Health Sciences, Inc., a Corporation Organized and Existing Under the Laws of the State of Nevada (The “Company”), Hereby Promises to Pay to Tfk Investments, LLC, Having Its Address at 1500 Nw 10th Ave., Suite 101, Boca Raton, Fl 33486, or Its Assigns (The “Holder” and Together With the Other Holders of Debentures Issued Pursuant to the Securities Purchase Agreement (As Defined Below), the “Holders”), the Initial Principal Sum of One Hundred Twenty Five Thousand and 00/100 Dollars ($125,000.00) (Subject to Adjustment as Provided Herein, the “Principal Amount”) on November 14, 2021 (The “Maturity Date”). the Company Has the Option to Redeem This Debenture Prior to the Maturity Date Pursuant to Section 2(b). All Unpaid Principal Due and Payable on the Maturity Date Shall Be Paid in the Form of Common Stock of the Company, Par Value $0.001 Per Share (“Common Stock”) Pursuant to Section 3. the Holder Has the Option to Cause Any Outstanding Principal and Accrued Interest, if Any, on This Debenture to Be Converted Into Common Stock at Any Time Prior to the Redemption Date (As Defined Below) or the Maturity Date Pursuant to Section 2(a). This Debenture Is One of the Debentures Referred to in the Securities Purchase Agreement (The “Securities Purchase Agreement”) Dated as of November 14, 2018, Between the Company and the Holder. Capitalized Terms Used but Not Defined Herein Shall Have the Meanings

from 8-K 14 pages Issuance Date: November 14, 2018 Principal Amount: $125,000.00 for Value Received, Parallax Health Sciences, Inc., a Corporation Organized and Existing Under the Laws of the State of Nevada (The “Company”), Hereby Promises to Pay to Peak One Opportunity Fund, L.P., Having Its Address at 333 South Hibiscus Drive, Miami Beach, Fl 33139, or Its Assigns (The “Holder” and Together With the Other Holders of Debentures Issued Pursuant to the Securities Purchase Agreement (As Defined Below), the “Holders”), the Initial Principal Sum of One Hundred Twenty Five Thousand and 00/100 Dollars ($125,000.00) (Subject to Adjustment as Provided Herein, the “Principal Amount”) on November 14, 2021 (The “Maturity Date”). the Company Has the Option to Redeem This Debenture Prior to the Maturity Date Pursuant to Section 2(b). All Unpaid Principal Due and Payable on the Maturity Date Shall Be Paid in the Form of Common Stock of the Company, Par Value $0.001 Per Share (“Common Stock”) Pursuant to Section 3. the Holder Has the Option to Cause Any Outstanding Principal and Accrued Interest, if Any, on This Debenture to Be Converted Into Common Stock at Any Time Prior to the Redemption Date (As Defined Below) or the Maturity Date Pursuant to Section 2(a). This Debenture Is One of the Debentures Referred to in the Securities Purchase Agreement (The “Securities Purchase Agreement”) Dated as of November 14, 2018, Between the Company and the Holder. Capitalized Terms Used but Not Defined Herein Shall Have the Meanings

from 10-K ~20 pages Parallax Health Sciences, Inc. 2016 Incentive Compensation Plan Parallax Health Sciences, Inc. 2016 Incentive Compensation Plan 1)

from 10-K ~20 pages Parallax Health Sciences, Inc. 2015 Incentive Compensation Plan Parallax Health Sciences, Inc. 2015 Incentive Compensation Plan 1)

from 8-K 2 pages Piggy-Back Registration Rights Agreement

from 8-K 2 pages Security Agreement

from 8-K 2 pages 12% Senior Secured Convertible Note

from 8-K 7 pages Stock Option Agreement